Cancer-associated fibroblast-derived PAI-1 promotes lymphatic metastasis via the induction of EndoMT in lymphatic endothelial cells.


Journal

Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647

Informations de publication

Date de publication:
06 Jul 2023
Historique:
received: 16 01 2023
accepted: 18 05 2023
medline: 10 7 2023
pubmed: 7 7 2023
entrez: 6 7 2023
Statut: epublish

Résumé

Endothelial-mesenchymal transition (EndoMT) is an emerging adaptive process that modulates lymphatic endothelial function to drive aberrant lymphatic vascularization in the tumour microenvironment (TME); however, the molecular determinants that govern the functional role of EndoMT remain unclear. Here, we show that cancer-associated fibroblast (CAF)-derived PAI-1 promoted the EndoMT of lymphatic endothelial cells (LECs) in cervical squamous cell carcinoma (CSCC). Immunofluorescent staining of α-SMA, LYVE-1 and DAPI were examined in primary tumour samples obtained from 57 CSCC patients. Assessment of cytokines secreted by CAFs and normal fibroblasts (NFs) was performed using human cytokine antibody arrays. The phenotype of EndoMT in lymphatic endothelial cells (LECs), gene expression levels, protein secretion and activity of signaling pathways were measured by real-time RT-PCR, ELISA or western blotting. The function of lymphatic endothelial monolayers was examined by transwell, tube formation assay, transendothelial migration assay in vitro. Lymphatic metastasis was measured using popliteal lymph node metastasis model. Furthermore, association between PAI-1 expression and EndoMT in CSCC was analyzed by immunohistochemistry. The Cancer Genome Atlas (TCGA) databases was used to assess the association of PAI-1 with survival rate in CSCC. CAF-derived PAI-1 promoted the EndoMT of LECs in CSCC. LECs undergoing EndoMT could initiate tumour neolymphangiogenesis that facilitated cancer cell intravasation/extravasation, which in turn promoted lymphatic metastasis in CSCC. Mechanistically, PAI-1 activated the AKT/ERK1/2 pathways by directly interacting with low-density lipoprotein receptor-related protein (LRP1), thereby leading to elevated EndoMT activity in LECs. Blockade of PAI-1 or inhibition of LRP1/AKT/ERK1/2 abrogated EndoMT and consequently attenuated CAF-induced tumour neolymphangiogenesis. Furthermore, clinical data revealed that increased PAI-1 levels positively correlated with EndoMT activity and poor prognosis in CSCC patients. Our data indicate that CAF-derived PAI-1 acts as an important neolymphangiogenesis-initiating molecular during CSCC progression through modulating the EndoMT of LECs, resulting in promotion of metastasis ability in primary site. PAI-1 could serve as an effective prognostic biomarker and therapeutic target for CSCC metastasis.

Sections du résumé

BACKGROUND BACKGROUND
Endothelial-mesenchymal transition (EndoMT) is an emerging adaptive process that modulates lymphatic endothelial function to drive aberrant lymphatic vascularization in the tumour microenvironment (TME); however, the molecular determinants that govern the functional role of EndoMT remain unclear. Here, we show that cancer-associated fibroblast (CAF)-derived PAI-1 promoted the EndoMT of lymphatic endothelial cells (LECs) in cervical squamous cell carcinoma (CSCC).
METHODS METHODS
Immunofluorescent staining of α-SMA, LYVE-1 and DAPI were examined in primary tumour samples obtained from 57 CSCC patients. Assessment of cytokines secreted by CAFs and normal fibroblasts (NFs) was performed using human cytokine antibody arrays. The phenotype of EndoMT in lymphatic endothelial cells (LECs), gene expression levels, protein secretion and activity of signaling pathways were measured by real-time RT-PCR, ELISA or western blotting. The function of lymphatic endothelial monolayers was examined by transwell, tube formation assay, transendothelial migration assay in vitro. Lymphatic metastasis was measured using popliteal lymph node metastasis model. Furthermore, association between PAI-1 expression and EndoMT in CSCC was analyzed by immunohistochemistry. The Cancer Genome Atlas (TCGA) databases was used to assess the association of PAI-1 with survival rate in CSCC.
RESULTS RESULTS
CAF-derived PAI-1 promoted the EndoMT of LECs in CSCC. LECs undergoing EndoMT could initiate tumour neolymphangiogenesis that facilitated cancer cell intravasation/extravasation, which in turn promoted lymphatic metastasis in CSCC. Mechanistically, PAI-1 activated the AKT/ERK1/2 pathways by directly interacting with low-density lipoprotein receptor-related protein (LRP1), thereby leading to elevated EndoMT activity in LECs. Blockade of PAI-1 or inhibition of LRP1/AKT/ERK1/2 abrogated EndoMT and consequently attenuated CAF-induced tumour neolymphangiogenesis. Furthermore, clinical data revealed that increased PAI-1 levels positively correlated with EndoMT activity and poor prognosis in CSCC patients.
CONCLUSION CONCLUSIONS
Our data indicate that CAF-derived PAI-1 acts as an important neolymphangiogenesis-initiating molecular during CSCC progression through modulating the EndoMT of LECs, resulting in promotion of metastasis ability in primary site. PAI-1 could serve as an effective prognostic biomarker and therapeutic target for CSCC metastasis.

Identifiants

pubmed: 37415190
doi: 10.1186/s13046-023-02714-0
pii: 10.1186/s13046-023-02714-0
pmc: PMC10324144
doi:

Substances chimiques

Plasminogen Activator Inhibitor 1 0
Proto-Oncogene Proteins c-akt EC 2.7.11.1
SERPINE1 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

160

Subventions

Organisme : National Natural Science Foundation of China
ID : 81971341
Organisme : National Natural Science Foundation of China
ID : 82102685
Organisme : National Natural Science Foundation of China
ID : 82173227
Organisme : Science and Technology Program of Guangzhou
ID : 202102020936
Organisme : Science and Technology Program of Guangzhou
ID : 202102021057
Organisme : Guangzhou Science and Technology Program key projects
ID : 202102010223
Organisme : Guangdong Basic and Applied Basic Research Foundation
ID : 2019A1515010872
Organisme : Guangdong Basic and Applied Basic Research Foundation-the Regional Joint
ID : 2019A1515110046

Informations de copyright

© 2023. The Author(s).

Références

Theranostics. 2019 Sep 23;9(24):7168-7183
pubmed: 31695760
Cancer Metastasis Rev. 2018 Sep;37(2-3):369-384
pubmed: 29858743
Front Cell Dev Biol. 2020 Aug 14;8:747
pubmed: 32923440
Mol Oncol. 2021 Jan;15(1):210-227
pubmed: 33124726
Nat Rev Cancer. 2014 Mar;14(3):159-72
pubmed: 24561443
Am J Physiol Heart Circ Physiol. 2016 May 1;310(9):H1055-63
pubmed: 26993222
J Clin Invest. 2016 May 2;126(5):1801-14
pubmed: 27043280
Nat Rev Gastroenterol Hepatol. 2019 May;16(5):282-295
pubmed: 30778141
J Biol Chem. 2010 May 7;285(19):14308-17
pubmed: 20220145
Cancer Lett. 2015 Jun 1;361(2):155-63
pubmed: 25700776
J Cell Mol Med. 2019 Apr;23(4):2984-2994
pubmed: 30734495
Angiogenesis. 2018 Aug;21(3):635-652
pubmed: 29675549
Cancer Res. 2015 Jan 15;75(2):284-95
pubmed: 25488750
Front Cardiovasc Med. 2020 Dec 22;7:622473
pubmed: 33415130
Cancer Res. 2014 Oct 1;74(19):5597-607
pubmed: 25142796
Nat Med. 1998 Aug;4(8):923-8
pubmed: 9701244
Mol Oncol. 2019 Aug;13(8):1706-1724
pubmed: 31094056
Front Immunol. 2019 Apr 09;10:720
pubmed: 31024552
Cancer Res. 2015 Aug 1;75(15):2969-74
pubmed: 26180080
Oncogene. 2017 Mar;36(11):1503-1515
pubmed: 27593938
Lab Invest. 2021 Mar;101(3):353-368
pubmed: 33311557
Curr Opin Immunol. 2018 Aug;53:7-12
pubmed: 29605736
Oncogene. 2021 Feb;40(8):1476-1489
pubmed: 33452453
J Transl Med. 2022 Jul 21;20(1):322
pubmed: 35864535
Cell Rep. 2020 Oct 13;33(2):108253
pubmed: 33053339
Science. 2020 Jul 10;369(6500):
pubmed: 32646971
Ups J Med Sci. 2015;120(3):135-43
pubmed: 26220421
J Clin Invest. 2001 Sep;108(6):779-84
pubmed: 11560943
Cell Death Dis. 2017 Dec 14;8(12):3220
pubmed: 29242498
Cell Death Dis. 2018 Jul 9;9(7):759
pubmed: 29988148
Cell Metab. 2019 Nov 5;30(5):917-936.e10
pubmed: 31447322

Auteurs

Wen-Fei Wei (WF)

Department of Gynaecology, Zhuhai People's Hospital (Zhuhai Hospital Affiliated With Jinan University), Zhuhai, 519000, Guangdong, China.
Department of Obstetrics and Gynaecology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.

Hui-Ling Zhou (HL)

Department of Obstetrics and Gynaecology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.

Pei-Yu Chen (PY)

Department of Obstetrics and Gynaecology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.

Xiao-Lan Huang (XL)

Department of Obstetrics and Gynaecology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.

Long Huang (L)

Department of Urology, Zhuhai People's Hospital (Zhuhai Hospital Affiliated With Jinan University), Zhuhai, 519000, Guangdong, China.

Luo-Jiao Liang (LJ)

Department of Obstetrics and Gynaecology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.

Chu-Hong Guo (CH)

Department of Obstetrics and Gynaecology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.

Chen-Fei Zhou (CF)

Department of Gynecology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, China.

Lan Yu (L)

Department of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, Guangdong, China.

Liang-Sheng Fan (LS)

Department of Obstetrics and Gynaecology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. fanyi0606@163.com.

Wei Wang (W)

Department of Gynaecology, Zhuhai People's Hospital (Zhuhai Hospital Affiliated With Jinan University), Zhuhai, 519000, Guangdong, China. smugowwang@126.com.
Department of Obstetrics and Gynaecology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. smugowwang@126.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH